Outcome parameter | Mean ± SD/ Median [P25–P75] |  | n (%) | |||
---|---|---|---|---|---|---|
Current HbA1c (% (mmol/mol)) | 7.8 ± 0.83 (62 ± 7.1) |  ≤ 7.0 (≤ 53) | 10 (18.5) | |||
7.1—8.0 (54—64) | 25 (46.3) | |||||
8.1—9.0 (65—75) | 16 (29.6) | |||||
 > 9.0 (> 75) | 3 (5.6) | |||||
Mean 10-years HbA1c (% (mmol/mol)) | 7.7 ± 0.63 (61 ± 5.8) | – | ||||
Skin AGEs (arbitrary units; AU) | 2.4 ± 0.47 | – | ||||
CV risk interpretation based on skin AGEs (n = 53) | – | Not increased | 7 (13.2) | |||
Mildly increased | 15 (28.3) | |||||
Moderately increased | 21 (39.6) | |||||
Strongly increased | 10 (18.9) | |||||
Urinary AGEs (emission:excitation-ratio) | 0.073 [0.047–0.115] | – | ||||
Serum sRAGE (pg/mL) | 908 [736–1172] | – | ||||
Skin AGEs-to-sRAGE ratio | 25.5 × 10–4 [18.61 × 10–4 − 32.17 × 10–4] |  | ||||
CGM- parameters | TIR (%) | 66 ± 12.9 | – | |||
TAR (%) | Total > 180 mg/dL | 30 ± 14.2 | ||||
Level 2 > 250 mg/dL | 5.5 [1.8–9.4] | |||||
TBR (%) | Total < 70 mg/dL | 3.6 [1.7–6.1] | ||||
Level 2 < 54 mg/dL | 0.5 [0.08–1.43] | |||||
CV (%) | 35 ± 6.1 |